Acadia pharmaceuticals announces phase 3 development candidate acp-101 (intranasal carbetocin) for prader-willi syndrome

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced the addition of a new phase 3 development candidate to its rare disease portfolio, acp-101 (intranasal carbetocin), for the treatment of hyperphagia (a false and unrelenting state of starvation) in prader-willi syndrome (pws). acadia acquired worldwide rights to develop and commercialize acp-101 with the acquisition of levo therapeutics in june 2022. “acadia's acquisition of acp-101 demonstrates our commitmen.
ACAD Ratings Summary
ACAD Quant Ranking